The use of agonistic anti-CD40 therapy in treatments for cancer
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowingthem to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an idealtherapy for c...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Taylor & Francis
2012
|
| Subjects: | |
| Online Access: | http://informahealthcare.com/loi/iri http://hdl.handle.net/20.500.11937/49580 |
| _version_ | 1848758270112563200 |
|---|---|
| author | Khong, A. Nelson, Delia nowak, A. Lake, R. Robinson, B. |
| author_facet | Khong, A. Nelson, Delia nowak, A. Lake, R. Robinson, B. |
| author_sort | Khong, A. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowingthem to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an idealtherapy for combination with traditional cancer treatments (i.e., chemotherapy, surgery) in orderto elicit immune-mediated anti-tumor effects. This review summarizes the mechanisms of actionof agonistic anti-CD40, the use of mouse models to investigate its effects and combinations withother therapies in vivo, and current clinical trials combining humanized anti-CD40 antibody withchemotherapy and/or other immunotherapies. |
| first_indexed | 2025-11-14T09:41:19Z |
| format | Journal Article |
| id | curtin-20.500.11937-49580 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:41:19Z |
| publishDate | 2012 |
| publisher | Taylor & Francis |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-495802017-03-15T22:55:23Z The use of agonistic anti-CD40 therapy in treatments for cancer Khong, A. Nelson, Delia nowak, A. Lake, R. Robinson, B. agonistic anti-CD40 immunotherapy mesothelioma cancer Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowingthem to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an idealtherapy for combination with traditional cancer treatments (i.e., chemotherapy, surgery) in orderto elicit immune-mediated anti-tumor effects. This review summarizes the mechanisms of actionof agonistic anti-CD40, the use of mouse models to investigate its effects and combinations withother therapies in vivo, and current clinical trials combining humanized anti-CD40 antibody withchemotherapy and/or other immunotherapies. 2012 Journal Article http://hdl.handle.net/20.500.11937/49580 http://informahealthcare.com/loi/iri Taylor & Francis restricted |
| spellingShingle | agonistic anti-CD40 immunotherapy mesothelioma cancer Khong, A. Nelson, Delia nowak, A. Lake, R. Robinson, B. The use of agonistic anti-CD40 therapy in treatments for cancer |
| title | The use of agonistic anti-CD40 therapy in treatments for cancer |
| title_full | The use of agonistic anti-CD40 therapy in treatments for cancer |
| title_fullStr | The use of agonistic anti-CD40 therapy in treatments for cancer |
| title_full_unstemmed | The use of agonistic anti-CD40 therapy in treatments for cancer |
| title_short | The use of agonistic anti-CD40 therapy in treatments for cancer |
| title_sort | use of agonistic anti-cd40 therapy in treatments for cancer |
| topic | agonistic anti-CD40 immunotherapy mesothelioma cancer |
| url | http://informahealthcare.com/loi/iri http://hdl.handle.net/20.500.11937/49580 |